These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 15900595

  • 1. Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker.
    Hirano T, Kato H, Maeda M, Gong Y, Shou Y, Nakamura M, Maeda J, Yashima K, Kato Y, Akimoto S, Ohira T, Tsuboi M, Ikeda N.
    Int J Cancer; 2005 Nov 10; 117(3):460-8. PubMed ID: 15900595
    [Abstract] [Full Text] [Related]

  • 2. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.
    Mathieu A, Remmelink M, D'Haene N, Penant S, Gaussin JF, Van Ginckel R, Darro F, Kiss R, Salmon I.
    Cancer; 2004 Oct 15; 101(8):1908-18. PubMed ID: 15386340
    [Abstract] [Full Text] [Related]

  • 3. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
    Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T, Saijo N.
    Cancer Res; 1991 Jun 15; 51(12):3237-42. PubMed ID: 1645616
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
    Miyatake K, Gemba K, Ueoka H, Nishii K, Kiura K, Tabata M, Shibayama T, Takigawa N, Kawaraya M, Tanimoto M.
    Anticancer Res; 2003 Jun 15; 23(3C):2829-36. PubMed ID: 12926120
    [Abstract] [Full Text] [Related]

  • 5. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
    Filipits M, Pirker R, Dunant A, Lantuejoul S, Schmid K, Huynh A, Haddad V, André F, Stahel R, Pignon JP, Soria JC, Popper HH, Le Chevalier T, Brambilla E.
    J Clin Oncol; 2007 Jul 01; 25(19):2735-40. PubMed ID: 17602078
    [Abstract] [Full Text] [Related]

  • 6. Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma.
    Bai F, Nakanishi Y, Kawasaki M, Takayama K, Yatsunami J, Pei XH, Tsuruta N, Wakamatsu K, Hara N.
    Cancer; 1996 Aug 01; 78(3):416-21. PubMed ID: 8697385
    [Abstract] [Full Text] [Related]

  • 7. Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: a retrospective study in Japan.
    Kenmotsu H, Ohde Y, Shukuya T, Eida H, Akamatsu H, Ono A, Nakamura Y, Tsuya A, Kaira K, Naito T, Murakami H, Takahashi T, Maniwa T, Isaka M, Endo M, Kondo H, Yamamoto N.
    Respir Investig; 2012 Dec 01; 50(4):157-61. PubMed ID: 23199980
    [Abstract] [Full Text] [Related]

  • 8. [Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer].
    Hirai Y, Yoshimasu T, Oura S, Tamaki T, Ota F, Nakamura R, Shimizu Y, Naito K, Ota M, Miyasaka M, Okamura Y, Nakamura Y, Yasuoka H, Kodama R.
    Gan To Kagaku Ryoho; 2009 Apr 01; 36(4):611-4. PubMed ID: 19381033
    [Abstract] [Full Text] [Related]

  • 9. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL, Hwang J, Perng RP, Whang-Peng J.
    Oncol Res; 1995 Apr 01; 7(1):31-8. PubMed ID: 7549042
    [Abstract] [Full Text] [Related]

  • 10. Glutathione-S transferase-pi expression in non small cell lung cancer in the assessment of response to chemotherapy.
    Unsal M, Akpolat I, Kandemir B.
    Saudi Med J; 2003 May 01; 24(5):493-8. PubMed ID: 12847624
    [Abstract] [Full Text] [Related]

  • 11. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
    Imaizumi M, Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan).
    Lung Cancer; 2005 Jul 01; 49(1):85-94. PubMed ID: 15949594
    [Abstract] [Full Text] [Related]

  • 12. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM, Lochrin CA, Darling G, Eady A, Newman TE, Evans WK.
    Cancer Prev Control; 1997 Dec 01; 1(5):366-78. PubMed ID: 9765759
    [Abstract] [Full Text] [Related]

  • 13. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
    Park TS, Kim HR, Koh JS, Jang SH, Hwang YI, Yoon HI, Chung JH, Kim CH, Kim SS, Kim WS, Jo J, Lee JC, Choi CM.
    Lung Cancer; 2014 Nov 01; 86(2):262-7. PubMed ID: 25261232
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small-cell lung cancer.
    Arai T, Yasuda Y, Takaya T, Hayakawa K, Toshima S, Shibuya C, Kashiki Y, Yoshimi N, Shibayama M.
    Cancer Detect Prev; 2000 Nov 01; 24(3):252-7. PubMed ID: 10975287
    [Abstract] [Full Text] [Related]

  • 15. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
    Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, Manguán-García C, Cejas P, López-Ríos F, Paz-Ares L, de CastroCarpeño J, Nistal M, Belda-Iniesta C, Perona R.
    Oncogene; 2010 Mar 18; 29(11):1681-90. PubMed ID: 20023704
    [Abstract] [Full Text] [Related]

  • 16. Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin.
    Okuyama T, Maehara Y, Endo K, Baba H, Adachi Y, Kuwano M, Sugimachi K.
    Cancer; 1994 Aug 15; 74(4):1230-6. PubMed ID: 8055443
    [Abstract] [Full Text] [Related]

  • 17. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients.
    Higashiyama M, Oda K, Okami J, Maeda J, Kodama K, Imamura F, Minamikawa K, Takano T, Kobayashi H.
    Lung Cancer; 2010 Jun 15; 68(3):472-7. PubMed ID: 19660825
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial.
    Dunant A, Pignon JP, Le Chevalier T.
    Clin Cancer Res; 2005 Jul 01; 11(13 Pt 2):5017s-5021s. PubMed ID: 16000606
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine.
    Imai H, Shukuya T, Yoshino R, Muraki K, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Tomizawa Y, Takahashi T, Takahashi K, Saito R, Yamamoto N.
    Chemotherapy; 2013 Jul 01; 59(4):307-13. PubMed ID: 24480845
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
    Pisters KM, Le Chevalier T.
    J Clin Oncol; 2005 May 10; 23(14):3270-8. PubMed ID: 15886314
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.